Pure Global
NCT06403501

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
Clascoterone
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
Feb 01, 2025
Enrollment
692 participants
Primary outcome

Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA),Change From Baseline in Non-inflammatory Lesion (NIL) Counts,Change From Baseline in Inflammatory Lesion (IL) Counts

Summary

The primary objective of this study is to determine the safety and efficacy of clascoterone
 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
 acne vulgaris.

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06403501
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06403501 through Pure Global AI's free database. This Phase 3 trial is sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 692 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.